.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

QuintilesIMS
Fuji
Express Scripts
Cantor Fitzgerald
Moodys
Baxter
Mallinckrodt
Harvard Business School
Fish and Richardson
Dow

Generated: June 24, 2017

DrugPatentWatch Database Preview

Nintedanib esylate - Generic Drug Details

« Back to Dashboard

What are the generic sources for nintedanib esylate and what is the scope of nintedanib esylate patent protection?

Nintedanib esylate
is the generic ingredient in one branded drug marketed by Boehringer Ingelheim and is included in one NDA. There are four patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Nintedanib esylate has one hundred and six patent family members in forty-three countries.

There is one drug master file entry for nintedanib esylate. One supplier is listed for this compound.

Summary for Generic Name: nintedanib esylate

Tradenames:1
Patents:4
Applicants:1
NDAs:1
Drug Master File Entries: see list1
Suppliers / Packagers: see list1
Bulk Api Vendors: see list16
Clinical Trials: see list59
Patent Applications: see list35
Formulation / Manufacturing:see details
Drug Prices:see low prices
DailyMed Link:nintedanib esylate at DailyMed

Pharmacology for Ingredient: nintedanib esylate

Drug ClassKinase Inhibitor
Mechanism of ActionProtein Kinase Inhibitors
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Boehringer Ingelheim
OFEV
nintedanib esylate
CAPSULE;ORAL205832-002Oct 15, 2014RXYesYes7,119,093► SubscribeYY ► Subscribe
Boehringer Ingelheim
OFEV
nintedanib esylate
CAPSULE;ORAL205832-002Oct 15, 2014RXYesYes► Subscribe► Subscribe
Boehringer Ingelheim
OFEV
nintedanib esylate
CAPSULE;ORAL205832-001Oct 15, 2014RXYesNo► Subscribe► Subscribe
Boehringer Ingelheim
OFEV
nintedanib esylate
CAPSULE;ORAL205832-001Oct 15, 2014RXYesNo7,989,474► Subscribe ► Subscribe
Boehringer Ingelheim
OFEV
nintedanib esylate
CAPSULE;ORAL205832-001Oct 15, 2014RXYesNo► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: nintedanib esylate

Country Document Number Estimated Expiration
Egypt25931► Subscribe
HungaryS1600022► Subscribe
Norway330486► Subscribe
Austria551322► Subscribe
Czech Republic20021410► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: NINTEDANIB ESYLATE

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
15/017Ireland► SubscribePRODUCT NAME: VARGATEF-NINTEDANIB, THE TAUTOMERS AND THE PHYSIOLOGICALLY ACCEPTABLE SALTS THEREOF; REGISTRATION NO/DATE: EU/1/14/954/001-004 20141121
90015-2Sweden► SubscribePRODUCT NAME: NINTEDANIB, THE TAUTOMERS AND THE SALTS THEREOF, IN PARTICULAR NINTEDANIB AND PHYSIOLOGICALLY ACCEPTABLE SALTS THEREOF, SPECIFICALLY NINTEDANIB ESILATE; REG. NO/DATE: EU/1/14/954 20141121
2015 00019Denmark► SubscribePRODUCT NAME: NINTEDANIB, TAUTOMERERNE OG SALTENE DERAF, SAERLIGT NINTEDANIB OG FYSIOLOGISK ACCEPTABLE SALTE DERAF, SPECIFIKT NINTEDANIB ESILAT; REG. NO/DATE: EU/1/14/954/001-004 20141121
2015015Lithuania► SubscribePRODUCT NAME: NINTEDANIBUM; REGISTRATION NO/DATE: EU/1/14/954/001-004 20141121
00725Netherlands► SubscribePRODUCT NAME: NINTEDANIB, DE TAUTOMEREN DAARVAN EN DE ZOUTEN DAARVAN, IN HET BIJZONDER NINTEDANIB EN FYSIOLOGISCH AANVAARDBARE ZOUTEN DAARVAN, MET NAME NINEDANIBESILAAT; REGISTRATION NO/DATE: EU/1/14/954/001-004 20141121
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Moodys
Chinese Patent Office
Daiichi Sankyo
Julphar
Healthtrust
Fish and Richardson
Cerilliant
US Army
UBS
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot